BioSpace News Archive

Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation of Athenex’s oral paclitaxel plus encequidar in combination with GSK’s dostarlimab in the neoadjuvant setting at this year’s American Society of Clinical Oncology (ASCO) conference.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for intravenous injection].

Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced Pete Stoy, formerly the company’s President and Chief Operating Officer, has assumed the role of Hanger’s Chief Executive Officer, effective immediately.

Celularity Inc. announced that Adrian Kilcoyne, M.D., M.P.H., M.B.A., Celularity’s Chief Medical Officer, will present data at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy, which will be held May 16-20th in Los Angeles.

Stryker reported operating results for the first quarter of 2023.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the first quarter ended March 31, 2023.

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced it will host a key opinion leader webinar on May 8, 2023 at 11:00 a.m. ET.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2023 financial results after market close on Monday, May 8, 2023.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023.